Floatz logo

Pomalidomide

Plasma Cell Myeloma

National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
59/ 100

Competitive context

474 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase Fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
Vincristine Sulfate
Roswell Park Cancer Institute
Phase 3BBB
Cyclosporin A
Seoul National University Hospital
Phase 3BBB
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
University of Birmingham
Phase 4BBB

View all 50 →

Same molecule, other indications

Pomalidomide is also rated in:

myelodysplastic syndromeActive
B
Indicative · Phase 2
63 / 100
View asset →
monoclonal paraproteinemia diseaseActive
B
Indicative · Phase 2
60 / 100
View asset →
primary central nervous system lymphomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →